WAVEMAN · COMPANY

UTHR · United Therapeutics Corp

LIVE

TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475

← ALL COMPANIES

UTHR

Name: UNITED THERAPEUTICS Corp (UTHR) insider trading and ownership data
Creator: WaveMan
License: https://wave-man.com/terms

UNITED THERAPEUTICS Corp

PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001082554

C-SUITE BUYING · 1CONGRESS · 1FORM 144 · 10☆ WATCH

INSIDER NET · 180D

-$852.9M

open-market buys minus sells, Form 4 codes P and S

INSIDER BUYERS · 180D

CONGRESS BUYERS · 1Y

FUNDS ADDED · QTR

425

13F, latest reported quarter

REVENUE GROWTH

+10.6%

XBRL, annual

NET MARGIN

41.9%

CONVERSIONS · 180D

188

codes C/M, not in net · $217.2M priced

SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST

INSIDERS

net -$852.9M over 180 days

-$360.7M over 90 days

the lowest in Pharma & Biotech

CONGRESS

1 member bought in the last year

the lowest in Pharma & Biotech

FUNDS

425 funds added or opened last quarter

more than 96% of Pharma & Biotech

REVENUE

+10.6% year over year

more than 61% of Pharma & Biotech

MARGIN

41.9% net margin

more than 95% of Pharma & Biotech

BUYBACKS

$1.5B repurchased, FY to 2026-06-30

more than 96% of Pharma & Biotech

SHORT

no short interest reported

THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET

Insiders are net sellers: -$852.9M across 9 people in 180 days.

425 funds added or opened positions in the latest 13F quarter, of 883 holders.

1 member of Congress reported buying it this year.

The year, with the filings on it

Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail

TOTAL 12M RETURN +21.5%

+21.5%12M

INSIDER SELLFORM 144

INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY

Live price

Daily candles from TradingView, on their licence — no filings are marked on this one

WHY THIS NAME IS ON THE DESK

Insiders have filed to sell — before selling.

The record shows a net $852.9M sold by insiders over 180 days, 425 funds added last quarter, 1 Congress member(s) bought in 12 months, $344.7M in planned Form 144 sales. Every figure is a federal filing, dated the day it became public.

Backtest this pattern Open the screener

Same sector, ranked by filing activity

Sector from the SEC's own SIC classification

CPIX MRNA REGN LLY ALNY ELF CITR MDGL DNA VRTX NUVL INSM

Insider transactions

Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, UNITED THERAPEUTICS Corp insiders sold a net $852.9M of stock across 4,776 Form 4 purchases and sales, with 1 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER

FILED

VALUE

MAHON PAUL A

EVP & GENERAL COUNSEL

SELL

2026-09-03

1,545.0

$740.0K

MAHON PAUL A

EVP & GENERAL COUNSEL

SELL

2026-09-03

936.0

$449.0K

MAHON PAUL A

EVP & GENERAL COUNSEL

SELL

2026-09-03

2,360.0

$1.1M

MAHON PAUL A

EVP & GENERAL COUNSEL

SELL

2026-09-03

1,048.0

$505.0K

MAHON PAUL A

EVP & GENERAL COUNSEL

SELL

2026-09-03

160.0

$77.2K

4,776 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 4,771 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders

13F · holdings as of the latest quarter funds have reported

BlackRock, Inc.

5,294,529.0 sh

$2.9B

Avoro Capital Advisors LLC

2,777,777.0 sh

$1.5B

VANGUARD PORTFOLIO MANAGEMENT LLC

1,919,429.0 sh

$1.0B

VANGUARD CAPITAL MANAGEMENT LLC

1,918,256.0 sh

$1.0B

STATE STREET CORP

1,898,064.0 sh

$1.0B

SCHEDULE 13D/G

No 5%+ ownership filings

Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.

Planned sales · Form 144

Filed before the sale — intent, not a trade

PAUL MAHON

FILED 2026-09-03

$4.0M

MARTINE ROTHBLATT

FILED 2026-09-01

$101.8M

PAUL MAHON

FILED 2026-08-20

$4.3M

PAUL MAHON

FILED 2026-08-06

$4.3M

MARTINE ROTHBLATT

FILED 2026-08-03

$103.3M

Fund concentration

N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show

Simplify Health Care ETF

$20.5M POSITION · AS OF 2026-03-31

8.8%

LIVE OAK HEALTH SCIENCES FUND

$3.2M POSITION · AS OF 2026-04-30

6.4%

Invesco Biotechnology & Genome ETF

$15.5M POSITION · AS OF 2026-04-30

6.3%

Poplar Forest Partners Fund

$20.4M POSITION · AS OF 2026-03-31

6.1%

Saratoga Health & Biotechnology Fund

$584.5K POSITION · AS OF 2026-02-28

5.0%

Franklin Genomic Advancements ETF

$996.2K POSITION · AS OF 2026-03-31

4.6%

SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK

Clinical pipeline

ClinicalTrials.gov · 30 registered trials, 8 still enrolling or running — a status change here is dated weeks before the press release

Phase 1

0 ACTIVE

Phase 2

0 ACTIVE

Phase 3

3 ACTIVE

Phase 4

1 ACTIVE

Not applicable

2 ACTIVE

Multi-phase

2 ACTIVE

TRIALS MATCHED TO THIS TICKER BY SPONSOR NAME · STUDIES RUN UNDER A SUBSIDIARY'S OWN NAME ARE NOT INCLUDED

Executive pay vs shareholder return · Martine Rothblatt

DEF 14A pay-versus-performance disclosure · both the headline pay and the SEC's mark-to-market figure, beside the return the company delivered and the return of the peer group it chose itself

CEO TOTAL

ACTUALLY PAID

OTHER NEOs AVG

TSR

PEER TSR

2025

$18.0M

$149.9M

$9.4M

+221%

+101%

2024

$23.0M

$120.3M

$10.0M

+132%

+56%

2023

$17.0M

-$10.8M

$7.0M

+45%

+44%

2022

$5.3M

$41.2M

$2.4M

+83%

+39%

2021

$3.5M

$50.4M

$2.0M

+42%

+24%

TAGGED BY THE COMPANY UNDER SEC ITEM 402(v) · RETURN IS CUMULATIVE FROM THE START OF THE DISCLOSURE PERIOD · GREEN WHERE THE COMPANY BEAT ITS OWN PEER GROUP

Fundamentals

Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all

	2025-12	2024-12	2023-12	2022-12
REVENUE	$3.2B	$2.9B	$2.3B	$1.9B
GROSS PROFIT	$2.8B	$2.6B	$2.1B	$1.8B
OPERATING INCOME	$1.5B	$1.4B	$1.2B	$979.7M
NET INCOME	$1.3B	$1.2B	$984.8M	$727.3M
EPS (DILUTED)	27.86	24.64	19.81	15.00
OPERATING CASH FLOW	$1.6B	$1.3B	$978.0M	$802.5M
CASH	$1.6B	$1.7B	$1.2B	$961.2M
BUYBACKS	$1.0B	$1.0B	$0	$0

SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE